Search

everythinglearnresearchcommunity

for

Search:↓

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Combining laser and corticosteroid is not better than corticosteroid alone for treating frontal fibrosing alopecia.

Finasteride-loaded microemulsions can effectively enhance skin delivery for treating hair loss.

Tofacitinib may help treat severe hair loss, but more research is needed.

The plant extract helped increase hair growth in men without severe side effects.

Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.

The cream effectively and safely reduces facial hair in women.

Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Apremilast did not work for treating severe alopecia areata.

NTF gel improves finasteride delivery for hair loss treatment, reducing side effects.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.

Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

The document's conclusion cannot be provided because the content is not accessible.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.